Becton Dickinson

BDX Health Care Market cap $49.8B as of Sep 14, 2026 16:00 ET S&P 500

Q3 FY26 Apr 1 – Jun 30, 2026 reported Aug 6, 2026

Revenue$4.98B −10% year over year

Gross profit$2.32B 46% margin

Operating profit$0.66B 13% margin

Net profit$0.38B 8% margin

The numbers behind the diagram

All figures in billions of U.S. dollars, for Q3 FY26 (period ends Jun 30, 2026).
Item	Value	Share of revenue	Year over year
Revenue	4.98	100%	−10%
Medical essentials	1.65	33%
Interventional	1.36	27%
Connected care	1.12	23%
BioPharma systems	0.59	12%
Other revenue	0.27	5%
Cost of revenue	−2.67	54%
Gross profit	2.32	46% margin	−1pp
R&D	−0.26	5%	+0pp
SG&A	−1.26	25%	+1pp
Other	−0.13	3%	+0pp
Operating profit	0.66	13% margin	−2pp
Interest & other costs	−0.18
Tax	−0.10
Net profit	0.38	8% margin

Figures are rounded to the precision shown, so a column can differ slightly from its own total.

Filing on EDGAR This quarter on its own page

All figures in billions of U.S. dollars, for Q2 FY26 (period ends Mar 31, 2026).
Item	Value	Share of revenue	Year over year
Revenue	4.71	100%	+5%
Medical essentials	1.65	35%	+5%
Interventional	1.36	29%	+7%
Connected care	1.12	24%	+5%
Bio pharma systems	0.59	12%	+3%
Cost of revenue	−2.56	54%
Gross profit	2.15	46% margin	+4pp
R&D	−0.25	5%	+0pp
SG&A	−1.21	26%	+1pp
Other	−0.60	13%	+0pp
Operating profit	0.09	2% margin	−7pp
Interest & other costs	−0.33
Tax	−0.08
Net profit	−0.31	−7% margin	−13pp

Figures are rounded to the precision shown, so a column can differ slightly from its own total.

Filing on EDGAR This quarter on its own page

All figures in billions of U.S. dollars, for Q1 FY26 (period ends Dec 31, 2025).
Item	Value	Share of revenue	Year over year
Revenue	5.25	100%	+2%
Medical essentials	1.60	30%
Interventional	1.33	25%	+6%
Connected care	1.13	22%
Life sciences	0.77	15%
Bio pharma systems	0.43	8%
Cost of revenue	−2.84	54%
Gross profit	2.41	46% margin	+3pp
R&D	−0.31	6%	−1pp
SG&A	−1.39	26%	+1pp
Other	−0.16	3%	+0pp
Operating profit	0.55	11% margin	+2pp
Interest & other costs	−0.17
Net profit	0.38	7% margin	+1pp

Figures are rounded to the precision shown, so a column can differ slightly from its own total.

Filing on EDGAR This quarter on its own page

All figures in billions of U.S. dollars, for Q4 FY25 (period ends Sep 30, 2025).
Item	Value	Share of revenue	Year over year
Revenue	6.68	100%	+23%
Cost of revenue	−3.49	52%
Gross profit	3.20	48% margin	+2pp
R&D	−0.39	6%	+0pp
SG&A	−1.52	23%	+0pp
Other	−0.42	6%	+0pp
Operating profit	0.86	13% margin	+1pp
Interest & other costs	−0.37
Net profit	0.49	7% margin	+0pp

Figures are rounded to the precision shown, so a column can differ slightly from its own total.

Filing on EDGAR This quarter on its own page

All figures in billions of U.S. dollars, for Q3 FY25 (period ends Jun 30, 2025).
Item	Value	Share of revenue	Year over year
Revenue	5.51	100%	+10%
Medical	2.93	53%
Interventional	1.33	24%
Life sciences	1.25	23%
Cost of revenue	−2.88	52%
Gross profit	2.63	48% margin	+2pp
R&D	−0.30	5%	−1pp
SG&A	−1.32	24%	+0pp
Other	−0.14	3%	+0pp
Operating profit	0.88	16% margin	+4pp
Interest & other costs	−0.18
Tax	−0.13
Net profit	0.57	10% margin	+1pp

Figures are rounded to the precision shown, so a column can differ slightly from its own total.

Filing on EDGAR This quarter on its own page

All figures in billions of U.S. dollars, for Q1 FY25 (period ends Dec 31, 2024).
Item	Value	Share of revenue	Year over year
Revenue	5.17	100%	+10%
Medical	2.62	51%	+17%
Life sciences	1.30	25%	+1%
Interventional	1.26	24%	+6%
Cost of revenue	−2.93	57%
Gross profit	2.24	43% margin	+0pp
R&D	−0.34	7%	+0pp
SG&A	−1.32	25%	+0pp
Other	−0.12	2%	+0pp
Operating profit	0.45	9% margin	−1pp
Interest & other costs	−0.15
Net profit	0.30	6% margin	+0pp

Figures are rounded to the precision shown, so a column can differ slightly from its own total.

Filing on EDGAR This quarter on its own page

Financial health

The balance sheet, the quarter's capital flow, the debt schedule and the capital structure of the quarter shown above.

Every set of results we hold, newest first. Open one on its own page.

Quarter	Period	Reported	Revenue	Year over year	Operating margin	Net profit	Net margin
Q3 FY26 Apr 1 – Jun 30, 2026 reported Aug 6, 2026 Operating margin 13% Net profit $0.38B	Apr 1 – Jun 30, 2026	Aug 6, 2026	$5.0B	−10%	13%	$0.38B	8%
Q2 FY26 Jan 1 – Mar 31, 2026 reported May 7, 2026 Operating margin 2% Net profit −$0.31B	Jan 1 – Mar 31, 2026	May 7, 2026	$4.7B	+5%	2%	−$0.31B	−7%
Q1 FY26 Oct 1 – Dec 31, 2025 reported Feb 9, 2026 Operating margin 11% Net profit $0.38B	Oct 1 – Dec 31, 2025	Feb 9, 2026	$5.3B	+2%	11%	$0.38B	7%
Q4 FY25 Jul 1 – Sep 30, 2025 reported Nov 25, 2025 Operating margin 13% Net profit $0.49B	Jul 1 – Sep 30, 2025	Nov 25, 2025	$6.7B	+23%	13%	$0.49B	7%
Q3 FY25 Apr 1 – Jun 30, 2025 reported Aug 7, 2025 Operating margin 16% Net profit $0.57B	Apr 1 – Jun 30, 2025	Aug 7, 2025	$5.5B	+10%	16%	$0.57B	10%
Q1 FY25 Oct 1 – Dec 31, 2024 reported Feb 6, 2025 Operating margin 9% Net profit $0.30B	Oct 1 – Dec 31, 2024	Feb 6, 2025	$5.2B	+10%	9%	$0.30B	6%